linjc16/ctgov huggingface dataset:
Quality of Image and Performance Diagnoses of the 3D Sequence of Cholangio-pancreatography MRI in Apnea With Compressed Acquisition

Study Overview
=================
Brief Summary
-----------------
The sequence of 3D CP-IRM, used in current practice in the protocols of bilio-pancreatic imaging, can be thus optimized to reduce acquisition time, thus the artefacts of movement, in particular in 3T. It remains however to estimate if the quality of obtained image is equivalent at least to that of the conventional sequence, without apnea, 3D CP-IRM. To summarize, the investigators suggest comparing the classic sequence (Fast Relaxation Fast Spin Echo (FRFSE) 3D) already existing with the same sequence to which will be added a technique of CS allowing its acquisition at shortened time(weather), with respiratory trigger on one hand and in apnea on the other hand. For the patient, this study will have for consequence only the addition of 2 sequence MRI, one of the 2 minutes 30 seconds (with respiratory trigger) and other one of the 20 seconds (in apnea).

Official Title
-----------------
Quality of Image and Performance Diagnoses of the 3D Sequence of Cholangio-pancreatography MRI in Apnea With Compressed Acquisition

Conditions
-----------------
Cholangiopancreatography

Intervention / Treatment
-----------------
* Diagnostic Test: CS plus FRFSE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age> 18 french understanding and speaking patient Pancreatic MRI prescription for bilio-pancreatic pathology Patient with medical insurance Exclusion Criteria: previous biliary surgery MRI contraindication Gadolinium recently injected (48 hours) Patient couldn't stay on apnea 20 seconds

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CS plus FRFSE<br>we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence | Diagnostic Test: CS plus FRFSE<br>* we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| image quality scale | Two senior radiologists will analyse the images of MRI with CS sequence | Day 1 |
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Study Overview
=================
Brief Summary
-----------------
To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.

Official Title
-----------------
A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension.

Conditions
-----------------
Glaucoma, Open-Angle, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Travoprost (0.004%)
* Drug: Latanoprost (0.005%)/Timolol (0.5%)


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Travoprost (0.004%)|nan|
|Drug: Latanoprost (0.005%)/Timolol (0.5%)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OAG, Glaucoma, POAG, OHT
A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China

Study Overview
=================
Brief Summary
-----------------
The primary objectives of this study were to evaluate the incidence of congenital CMV infection in neonates, and assess the concordance of detecting congenital cytomegalovirus (CMV) infection in neonatal saliva and urine samples.

Detailed Description
-----------------
This Cross-sectional study was conducted to recruit neonates less than 14 days old delivered in Maternal and Child Health Hospitals (MCHHs) of Xinmi City, Jiaxian County, Zhongmu County and Huli District Xiamen City, in China, from June 2015 to June 2016. The aim of this study is to enroll  1800 neonates, and collect their saliva and urine samples which will be tested the CMV DNA by using real-time PCR.

Conditions
-----------------
Congenital Cytomegalovirus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates aged 0 to 14 days Neonates delivered in MCHHs of Xinmi City, Jiaxian County, Zhongmu County and Huli District Xiamen City Exclusion Criteria: the parents of neonates not comply with our study

Ages Eligible for Study
-----------------
Maximum Age: 14 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cCMV infection in newborns |  | up to 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the Kappa value of CMV prevalence between saliva and urine samples |  | up to 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytomegalovirus
Does Amniotic Fluid Index Affect the Fetal Cardiac Performance?

Study Overview
=================
Brief Summary
-----------------
To evaluate and compare fetal cardiac performance by fetal echocardiography and delivery outcome between fetuses with isolated oligohydramnios, normal amniotic fluid and polyhydramnios.

Official Title
-----------------
Does the Amniotic Fluid Index Affect the Fetal Cardiac Performance?

Conditions
-----------------
Oligohydramnios, Polyhydramnios

Intervention / Treatment
-----------------
* Other: Echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age 24-42 weeks Singleton pregnancies Exclusion Criteria: Fetal anatomical or chromosomal abnormality Known fetal cardiac defect Suspected fetal infection Suspected IUGR

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Isolated Oligohydramnios<br>Fetuses with amniotic fluid index (AFI) equal or less than 5 cm | Other: Echocardiography<br>* Imaging of fetal heart and amniotic fluid<br>|
| Isolated Polyhydramnios<br>Fetuses with amniotic fluid index (AFI) more than 25 cm | Other: Echocardiography<br>* Imaging of fetal heart and amniotic fluid<br>|
| Control Group<br>Fetuses with normal amount of amniotic fluid | Other: Echocardiography<br>* Imaging of fetal heart and amniotic fluid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal cardiac ventricles | The width of the fetal cardiac ventricles will be measured and compared between all three groups | One month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gestational age | Gestational age at delivery will be compared between the three groups | One month | 
| Mode of delivery | Mode of delivery will be compared between the three groups | One month | 
| Birth weight | Birth weight will be compared between the three groups | One month |
Articaine 4% Efficacy and Safety in Extraction and Pulpotomy of Primary Molars of Children Below the Age of Four Years

Study Overview
=================
Brief Summary
-----------------
compare the anaesthetic efficacy and safety for pain and behaviour for extraction or pulp therapy in primary molars in young children below four years old using 4% articaine and 2% lidocaine local anesthetics.

Official Title
-----------------
Articaine 4% Efficacy and Safety in Extraction and Pulpotomy of Primary Molars of Children Below the Age of Four Years.

Conditions
-----------------
Pain, Behavior

Intervention / Treatment
-----------------
* Drug: Lidocain hydrochloride 2 % with epinephrine
* Drug: Articaine chloride 4% with epinephrine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children 3-6 years primary molar indicated for pulpotomy body weight not less than 15 Kg Exclusion Criteria: Intellectual problem sever emotional problems previous dental experience Medically or mentally compromised children

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lidocaine<br>Lidocain hydrochloride 2 %with epinephrine 1:100000 | Drug: Lidocain hydrochloride 2 % with epinephrine<br>* Local anesthesia infilteration in children<br>|
| Experimental: Articaine<br>Articaine chloride 4% with epinephrine 1:100000 | Drug: Articaine chloride 4% with epinephrine<br>* Articaine chloride 4% with epinephrine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intra and post operative pain | Evaluate pain during injection and treatment using FLACC (face,legs,activity, cry, consolabolity) scale | 30-60 minutes | 
| Behavior | Evaluate child behavior using frankl scale during treatment | 30-60 minutes | 
| Blood pressure | Vital signs | 30-60 minutes | 
| Heart rate | Vital signs | 30-60 minutes | 
| Respiratory rate measuring during treatment | Vital signs | 30-60 minutes |
Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
This study enrolled patients with measurable metastatic colorectal cancer. Blood was drawn prior to the patient receiving a new therapy for his/her cancer and subsequently at 7-14 days, 3-4 weeks, and when an imaging study was done ( every 6 to 12 weeks). The blood was tested to find circulating tumor cells (CTCs) and to count them. The CTC levels were compared to the imaging study results to see if the CTC number and the imaging result (progression/no progression) were in agreement. Maximum active study participation was 12 months with up to 8 blood draws being taken. All patients are currently being followed for up to 24 months from their off study date for survival. The CTC result will also be used to see if there is a difference in survival and progression-free survival for those patients with and without a certain number of CTCs.

Official Title
-----------------
Longitudinal Enumeration of Circulating Tumor Cells in Patients With Metastatic Colorectal Carcinomas

Conditions
-----------------
Colorectal Cancer, Neoplasm Metastasis

Intervention / Treatment
-----------------
* Procedure: Phlebotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Measurable metastatic carcinoma of the colon or rectum. 1st or 2nd line chemotherapy (3rd line acceptable with epidermal growth factor receptor [EGFR] targeted therapy) Chest/abdomen/pelvis scans every 6-12 weeks ECOG 0-2 Hemoglobin (Hgb) > or = 8g/dl within 7 days prior to enrollment Age > or = to 18 years of age Exclusion Criteria: Cumulative weekly blood draws exceeding 150mL/week Brain metastasis Prior history of other carcinoma within the last 5 years, except ductal carcinoma in situ (DCIS), non-invasive cervical cancer or non-melanoma skin cancer Surgery within 14 days of the initial blood draw, excluding surgical placement of a central venous device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br>Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy. | Procedure: Phlebotomy<br>* Peripheral blood draws for testing of circulating tumor cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metastatic colorectal cancer
Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female patients who receive the palonosetron or not.

Detailed Description
-----------------
Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.

Official Title
-----------------
Effect of Palonosetron on Effect-site Concentration of Remifentanil for Preventing Emergence Cough During General Anesthesia in Female Patients Undergoing Laparoscopic Cholecystectomy

Conditions
-----------------
Gallbladder Diseases

Intervention / Treatment
-----------------
* Drug: Normal saline injection
* Drug: Palonosetron Injection [Aloxi]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Laparoscopic cholecystectomy under general anesthesia Exclusion Criteria: BMI > 30 kg/m2, respiratory infection, uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br>Control group receives the intravenous normal saline 2 mL. | Drug: Normal saline injection<br>* Normal saline 2 mL, intravenous injection<br>|
| Experimental: Palonosetron group<br>Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL. | Drug: Palonosetron Injection [Aloxi]<br>* Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| optimal Ce of remifentanil | Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia | From the end of surgery until the time of endotracheal extubation, about 20 minutes |
Tension Versus no Tension With Foley Bulb Induction

Study Overview
=================
Brief Summary
-----------------
To compare the application of tension versus no tension in Foley transcervical catheters for pre-induction cervical ripening.

Detailed Description
-----------------
Patients who are scheduled to undergo labor induction will be offered inclusion in the study which will attempt to determine if placing tension on the foley ballon will shorten the interval between induction initiation and delivery.

Official Title
-----------------
A Prospective, Randomized Comparison of Tension Versus no Tension With Foley Transcervical Catheters for Pre-induction Cervical Ripening

Conditions
-----------------
Induction of Labor Affected Fetus / Newborn

Intervention / Treatment
-----------------
* Procedure: Tension
* Procedure: NO TENSION


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nulliparas with singleton live intrauterine pregnancies undergoing labor induction at Kapiolani Medical Center for Women and Children. Cephalic presentation Intact fetal membranes Bishop score less than or equal to 6 Age greater than or equal to 18 years Exclusion Criteria: Multiparas Multiple gestation Previous uterine/cervical surgery Ruptured fetal membranes Fetal malpresentation Any contraindication to vaginal delivery at time of admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tension<br>foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault. | Procedure: Tension<br>* Tension applied to catheter and taped firmly to leg.<br>* Other names: misoprostil 25 mcg;|
| Active Comparator: No tension<br>The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault. | Procedure: NO TENSION<br>* Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same<br>* Other names: misoprostil 25 mcg;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Delivery | Reduction in time to delivery | Will measure length of time from beginning of induction with the foley balloon until delivery |
Pharmacogenetics of Vitamin D Supplementation in Tuberculosis

Study Overview
=================
Brief Summary
-----------------
Previous studies of vitamin D supplementation have suggested there may be differences in response between individuals. This study is an open label study of vitamin D supplementation in patients with active or latent tuberculosis in which active disease patients take 100000units of vitamin D every 8 weeks during their tuberculosis treatment. Genotyping for relevant vitamin D pathway polymorphisms will be carried out and related to clinical and ex vivo markers of vitamin D response. Latent patients will only be studied for vitamin D response ex vivo. Our hypothesis is that response to vitamin D in both monocytes and T cells will be related to polymorphisms in the DBP gene, and that this may relate to clinical response in terms of post supplementation vitamin D level.

Official Title
-----------------
The Pharmacogenetics of Vitamin D Supplementation in Tuberculosis

Conditions
-----------------
Tuberculosis

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 16 or above Microbiologically or histologically confirmed active tuberculosis Clinically confirmed latent tuberculosis Exclusion Criteria: Patients being managed with regimes outside standard NICE guidance Drug resistant MTb HIV positive Known intolerance of vitamin D Sarcoidosis Hyperparathyroidism or nephrolithiasis Taking vitamin D supplementation in the two months preceding enrolment Baseline serum corrected calcium >2.65 mmol/L Current haemodialysis Children, pregnant or breastfeeding individuals Concomitant benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, phenytoin, primidone or long-term immunosuppressant therapy

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D<br> | Dietary Supplement: Vitamin D<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in post supplementation vitamin D level |  | 8,16 and 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ex vivo responses of monocytes to vitamin D |  | 0 and 8 weeks | 
| Ex vivo responses of T cells to vitamin D |  | 0 and 8 weeks |